CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.04B, above the global median of $1.18B
- FinancialsAltman Z-Score 7.78: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.46%
Annual Rate
CNY 0.65Paid semi-annual
Payout Ratio
166.7%High
Payback Period
41.9 yr
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.67BCNY2.04B · vs all stocks (USD)
Revenue (TTM)
1.47BCNY219.74M · vs all stocks (USD)
Profit Margin
-0.60%vs Biotechnology peers
Beta
0.6820xvs all stocks
52-Week Change
58.60%vs all stocks
Market Capitalization
13.67BCNY2.04B · vs all stocks (USD)
Enterprise Value
9.42BCNY1.41B · vs all stocks (USD)
Forward P/E
62.02xvs Biotechnology peers
Price to Sales (TTM)
8.04xvs Biotechnology peers
Price to Book (MRQ)
3.28xvs Biotechnology peers
Enterprise to Revenue
6.40xvs Biotechnology peers
Gross Margin
69.60%vs Biotechnology peers
Profit Margin
-0.60%vs Biotechnology peers
Operating Margin
-5.05%vs Biotechnology peers
Return on Assets (TTM)
-1.20%vs Biotechnology peers
Return on Equity (TTM)
-0.50%vs Biotechnology peers
Revenue (TTM)
1.47BCNY219.74M · vs all stocks (USD)
Revenue per Share (TTM)
2.57CNYUpdated Sep 22, 2026Quarterly Revenue Growth
18.20%vs Biotechnology peers
Gross Profit (TTM)
980.46MCNY146.35M · vs all stocks (USD)
EBITDA (TTM)
139.86MCNY20.88M · vs all stocks (USD)
Net Income (TTM)
-8.78MCNY-1.31M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
456.10%vs Biotechnology peers
Operating Cash Flow (TTM)
255.35MCNY38.12M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
222.35MCNY33.19M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
2.46%vs all stocks
Payout Ratio
166.67%vs Biotechnology peers
Minority Interest (Equity)
-4.82MCNYFY2025 · Dec 31, 2025Revenue
1.38BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
419.66MCNYFY2025 · Dec 31, 2025Gross Profit
958.22MCNYFY2025 · Dec 31, 2025Operating Income
-35.82MCNY-5.35M · vs all stocks (USD)
Pre-tax Income
-37.71MCNYFY2025 · Dec 31, 2025Income Tax Expense
-15.20MCNYFY2025 · Dec 31, 2025Net Income
-22.51MCNYFY2025 · Dec 31, 2025EBIT
-13.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
139.86MCNYFY2025 · Dec 31, 2025Research & Development
280.67MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
213.90MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.31MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
24.17MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0308CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0308CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
539.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
539.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-22.51MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
34.87MCNYFY2025 · Dec 31, 2025Free Cash Flow
-9.35MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
197.23MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-22.51MCNYFY2025 · Dec 31, 2025Other Non-cash Items
74.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
22.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-40.36MCNYFY2025 · Dec 31, 2025Capital Expenditures
-44.22MCNYFY2025 · Dec 31, 2025Purchase of Investments
-8.44BCNYFY2025 · Dec 31, 2025Sale of Investments
8.17BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-320.03MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
919.39MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-941.36MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-77.46MCNYFY2025 · Dec 31, 2025Other Financing Charges
-42.62MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-142.05MCNYFY2025 · Dec 31, 2025Shares Outstanding
516.99MSharesUpdated Sep 22, 2026Float Shares
175.86MSharesUpdated Sep 22, 2026% Held by Insiders
69.50%vs all stocks
% Held by Institutions
9.49%vs all stocks
Total Cash (MRQ)
2.51BCNY374.91M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.86CNYUpdated Sep 22, 2026Total Debt (MRQ)
671.57MCNY100.25M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1864xvs Biotechnology peers
Current Ratio (MRQ)
3.99xvs Biotechnology peers
Book Value per Share (MRQ)
6.98CNYUpdated Sep 22, 2026Total Assets
5.03BCNY750.53M · vs all stocks (USD)
Total Current Assets
3.71BCNYFY2025 · Dec 31, 2025Total Liabilities
1.24BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.32BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
194.88MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.04BCNYFY2025 · Dec 31, 2025Cash
784.83MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.07MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
804.90MCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.05BCNYFY2025 · Dec 31, 2025Accounts Receivable
444.01MCNYFY2025 · Dec 31, 2025Inventory
343.67MCNYFY2025 · Dec 31, 2025Accounts Payable
91.59MCNYFY2025 · Dec 31, 2025Short-term Debt
715.11MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.57MCNYFY2025 · Dec 31, 2025Long-term Debt
127.33MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.75MCNYFY2025 · Dec 31, 2025Common Stock (Book)
397.73MCNYFY2025 · Dec 31, 2025Retained Earnings
861.73MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.79BCNY565.92M · vs all stocks (USD)
Treasury Stock
3.00MCNYFY2025 · Dec 31, 202552-Week Low
12.89CNYUpdated Sep 22, 202652-Week High
27.60CNYUpdated Sep 22, 202652-Week Change
58.60%vs all stocks
Beta
0.6820xvs all stocks
50-Day MA
20.30CNYUpdated Sep 22, 2026200-Day MA
16.81CNYUpdated Sep 22, 2026Avg 10-Day Volume
10.32MSharesUpdated Sep 22, 2026Avg 30-Day Volume
14.25MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.0100CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.01
Financial Health
Altman Z-Score 7.78: safe zoneNotable
Altman Z-Score: 7.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.04B, above the global median of $1.18BNotable
Market cap (USD): 2,041,156,035.192Global Median: 1,180,223,658.953
Levered free cash flow is $33.19M, above the global median of $18.73MNotable
Levered free cash flow (USD): 33,190,504.535Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vericel Corporation
Tier 1ProductionApproval-Gated PipelineRule
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow